Avidity Biosciences

RNA Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$13.44

-0.22% today

52W: $11.95 – $16.77

52W Low: $11.95 Position: 30.9% 52W High: $16.77

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

11.2x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$208.5M

Market Capitalization

Revenue Growth

-71.1%

YoY Revenue Growth

Profit Margin

-265.88%

Net profit margin

ROE

—

Return on Equity

Beta

—

Market sensitivity

Short Interest

—

% of float sold short

Avg. Volume

1,237,004

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

1 analysts

Avg. Price Target

$25.00

+86.01% upside

Target Range

$25.00 – $25.00

About the Company

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.

Sector: Healthcare Industry: Biotechnology Country: United States Exchange: NMS